Effects of rifabutin and rifampicin on the pharmacokinetics of ethinylestradiol and norethindrone

Journal of Clinical Pharmacology

Volumn 38, Issue 11, 1998, Pages 1042-1050

  LeBel, Marc ^a,b   Masson, Eric ^a,b   Guilbert, Edith ^c   Colborn, Dave ^e   Paquet, Francois ^a   Allard, Sylvie ^a   Vallée, François ^a   Narang, Prem K ^d  

^a Anapharm Canada   (Canada)

^b UNIVERSITÉ LAVAL   (Canada)

^c LAVAL UNIVERSITY   (Canada)

^d PFIZER INC   (United States)

^e Pharmacia and Upjohn ^*

Author keywords

[No Author keywords available]

Indexed keywords

FOLLITROPIN; LUTEINIZING HORMONE; MESTRANOL PLUS NORETHISTERONE; ORAL CONTRACEPTIVE AGENT; PROGESTERONE; RIFABUTIN; RIFAMPICIN; TUBERCULOSTATIC AGENT;

ADULT; ANTIBIOTIC THERAPY; AREA UNDER THE CURVE; ARTICLE; BIRTH CONTROL; CLINICAL TRIAL; CONTRACEPTION; CROSSOVER PROCEDURE; DRUG HALF LIFE; DRUG METABOLISM; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; NORMAL HUMAN; ORAL CONTRACEPTION; ORAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL; PREMENOPAUSE;

EID: 0031727339     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/009127009803801109     Document Type: Article

References (34)

1. Boroditsky R, Fisher W, Sand M: The 1995 Canadian Contraception Study. J Soc Ob Gyn Can 1996;18:1-31.
2. Mishell DR: Contraception. N Engl J Med 1989;320:777-787.
3. Williams CL, Stancel GM: Estrogens and progestins. In, Hardman JG, Limbird LE, Molinoff PB, Ruddon RW, (eds.): Goodman and Gilman's The Pharmacological Basis of Therapeutics. Ninth edition. Toronto: Pergamon Press, 1996;1411-1440.
4. Back DJ, Orme ML: Pharmacokinetic drug interactions with oral contraceptives. Clin Pharmacokinet 1990;18:472-484.
5. Back DJ, Grimmer SF, Orme ML, Proudlove C, Mann RD, Breckenridge AM: Evaluation of Committee on Safety of Medicines yellow card reports on oral contraceptive-drug interactions with anticonvulsants and antibiotics. Br J Clin Pharmacol 1988;25:527-532.
6. Back DJ, Orme ML: Drug interactions. In, Goldzieher JW (ed.): Pharmacology of the Contraceptive Steroids. New York: Raven Press, 1994;407-425.
7. Fazio A: Oral contraceptive drug interaction: important considerations. South Med J 1991;84:997-1002.
8. van Kijke CPH, Weber JCP: Interaction between oral contraceptives and griseofulvin. Br Med J 1984;288:1125-1126.
9. Guengerich FP: Metabolism of 17 alpha-ethynylestradiol in humans. Life Sci 1990;47:1981-1988.
10. Schuetz EG, Schinkel AH, Relling MV, Schuetz JD: P-glycoprotein: a major determinant of rifampicin-inducible expression of cytochrome P4503A in mice and humans. Proc Natl Acad Sci U S A 1996;93:4001-4005.
11. Back DJ, Breckenridge AM, Crawford F, Maclver M, Orme ML, Park BK, et al: The effect of rifampicin on noresthisterone pharmacokinetics. Eur J Clin Pharmacol 1979;15:193-197.
12. Bolt HM, Bolt M, Kappus H: Interaction of rifampicin treatment with pharmacokinetics and metabolism of ethinyloestradiol in man. Acta Endocrinol 1977;85:189-197.
13. Joshi JV, Joshi UM, Sankolli GM, Gupta K, Rao AP, Hazari K, et al: A study of interaction of a low-dose combination oral contraceptive with anti-tubercular drugs. Contraception 1980;21:617-627.
14. Combalbert J, Fabre I, Febre G, Dalet I, Derancourt J: Metabolism of cyclosporin A. IV. Purification and identificatino of the rifampicin-inducible human liver cytochrome P450IIIA gene subfamily. Drug Metab Dispos 1989;17:197-207.
15. Skinner MH, Blaschke TF: Clinical pharmacokinetics of rifabutin. Clin Pharmacokinet 1995;28:115-125.
16. Maddix DS, Talllian KB, Mead PS: Rifabutin: a review with emphasis on its role in the prevention of disseminated mycobacterium avium complex infection. Ann Pharmacother 1994;28:1250-1254.
17. Braun Trapnell C, Jamis-Dow C, Klecker RW, Collins JM: Metabolism of rifabutin and its 25-desacetyl metabolite, LM565, by human liver microsomes and recombinant human cytochrome P-450 3A4: relevance to clinical interaction with fluconazole. Antimicrob Agents Chemother 1997;41:924-926.
18. Iatsimirskaia E, Tulebaev S, Storozhuk E, Utkin I, Smith D, Gerber N, et al: Metabolism of rifabutin in human enterocyte and liver microsomes: kinetic parameters, identification of enzyme systems, and drug interactions with macrolides and antifungal agents. Clin Pharmacol Ther 1997;61:554-562.
19. Piscitelli SC, Flexner C, Minor JR, Polis MA, Masur H: Drug interactions in patients infected with human immunodeficiency virus. Clin Infect Dis 1996;23:685-693.
20. Perucca E, Grimaldi R, Frigo GM, Sardi A, Mönig H, Ohnhaus EE: Comparative effects of rifabutin and rifampicin on hepatic microsomal enzyme activity in normal subjects. Eur J Clin Pharmacol 1988;34:595-599.
21. Gibaldi M, Perrier D: Pharmacokinetics. Second edition. New York: Marcel Dekker, 1982.
22. World Health Organization: WHO common toxicity criteria. Cancer 1981;417:207-214.
23. Back DJ, Breckenridge AM, Crawford FE, Hall JM, Maclver M, Orme ML, et al: The effect of rifampicin on the pharmacokinetics of ethynylestradiol in women. Contraception 1980;21:135-143.
24. Reimers D, Jezel A: Rifampin und ander antituberkulotika bei gleichzeitiger oraler kontrazeption, Prax Pneumol 1971;25:255-262.
25. Nock-Finck L, Breuer H, Reimers D: Effects of rifampin on menstrual cycle and on estrogen excretion in patients taking oral contraceptives. Dtsch Med Wochenschr 1973;98:1521-1523.
26. Watkins PB, Wrighton SA, Maurel P, Schuetz EG, Mendez-Picon G, Parker GA, et al: Identification of an inducible form of cytochrome P-450 in human liver. Proc Natl Acad Sci U S A 1985;82:6310-6314.
27. Vandevelde C, Chang A, Andrews D: Rifampin and ansamycin interactions with cyclosporine after renal transplantation. Pharmacotherapy 1991;11:88-91.
28. Kocarek TA, Schuetz EG, Strom SC, Fisher RA, Guzelian PS: Comparative analysis of cytochrome P4503A induction in primary cultures of rat, rabbit, and human hepatocytes. Drug Metab Dispos 1995;23:415-421.
29. Fraser IS, Lansen RPS: Why do inadvertent pregnancies occur in oral contraceptive users? Effectiveness of oral contraceptive regimens and interfering factors. Contraception 1983;27:531-551.
30. Apseloff G, Fluids G, LaBoy-Goral L, Kraut E, Vincent J: Severe neutropenia caused by recommended prophylactic doses of rifabutin (letter). Lancet 1996;348:1598.
31. Tansey MJ, Moe JB: Severe neutropenia and prophylactic doses of rifabutin (letter). JAMA 1998;348:685.
32. Narang PK, Lewis RC, Bianchine JR: Rifabutin absorption in humans: relative bioavailability and food effect. Clin Pharmacol Ther 1992;52:335-341.
33. Strolin Benedetti M, Efthymiopoulos C, Sasselta D: Autoinduction of rifabutin metabolism in man. Xenobiotica 1990;20:1113-1119.
34. Strolin Benedetti M, Dostert P: Induction and autoinduction properties of rifamycin derivatives: a review of animal and human studies. Environ Health Perspect 1994;102(Suppl 9):101-105.